NCT06267794View on ClinicalTrials.gov

Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

June 26, 2015

Primary Completion Date

December 30, 2021

Study Completion Date

March 24, 2023

Conditions
Liver FibrosisCirrhosis, LiverChronic Liver Disease
Interventions
DRUG

Pirfenidone 1200 mg

1200 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.

DRUG

Pirfenidone 1800 mg

1800 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.

DRUG

Placebo

0 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.

All Listed Sponsors
lead

Jorge L Poo

OTHER

NCT06267794 - Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis. | Biotech Hunter | Biotech Hunter